Drug intelligence / Profile preview

Cabedol

Development stage: Unknown
Lead developer: Megat Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

**Cabedol** is an oral fixed-dose antimigraine product marketed by Megat in Ecuador for symptomatic treatment of migraine-associated headache. Each coated tablet contains acetaminophen 650 mg, caffeine 50 mg, and dihydroergotamine mesylate 1 mg. Dihydroergotamine provides antimigraine activity principally through serotonin 5-HT1D receptor agonism, while caffeine antagonizes adenosine receptors and may augment the vasoconstrictive effect of dihydroergotamine; acetaminophen provides analgesic activity through a mechanism that is not fully established. ([quickmed.edifarm.com.ec](https://quickmed.edifarm.com.ec/ficha/14707/cabedol))

Brand names: Cabedol

Targets

ADORA1 (Adenosine receptor A1 subtype)HTR1D (5-hydroxytryptamine receptor 1D)HTR1B (5-Hydroxytryptamine Receptor 1B)ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on Cabedol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cabedol.

Explore the full profile